FDA
- Status: approved
Basal insulin glargine and lixisenatide (Basal insulin glargine and lixisenatide) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
LMC Diabetes & Endocrinology Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.